MX2018001722A - Derivados del acido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridi n-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana. - Google Patents

Derivados del acido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridi n-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana.

Info

Publication number
MX2018001722A
MX2018001722A MX2018001722A MX2018001722A MX2018001722A MX 2018001722 A MX2018001722 A MX 2018001722A MX 2018001722 A MX2018001722 A MX 2018001722A MX 2018001722 A MX2018001722 A MX 2018001722A MX 2018001722 A MX2018001722 A MX 2018001722A
Authority
MX
Mexico
Prior art keywords
alkyl
alkoxy
compounds
tetrahydroisoquinolin
pyridin
Prior art date
Application number
MX2018001722A
Other languages
English (en)
Inventor
F Kadow John
Narasimhulu Naidu B
Wang Tao
J Eastman Kyle
E Parcella Kyle
Yin Zhiwei
Zhang Zhongxing
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56851651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018001722(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MX2018001722A publication Critical patent/MX2018001722A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se divulgan compuestos de Fórmula I, incluyendo sales farmacéuticamente aceptables, composiciones farmacéuticas que comprenden los compuestos, procedimientos de preparación de los compuestos y su uso en la inhibición de la integrasa del VIH y tratamiento de infectados con el VIH o SIDA. En los compuestos de la fórmula (I); R1 está seleccionado de hidrógeno, alquilo o cicloalquilo; R2 está seleccionado de tetrahidroisoquinolinilo y está sustituido con 1 sustituyente R6 y también con 0-3 sustituyentes halo o alquilo; R3 está seleccionado de azetidinilo, pirrolidinilo, piperidinilo, piperazinilo, morfolinilo, homopiperidinilo, homopiperazinilo u homomorfolinilo, y está sustituido con 0-3 sustituyentes seleccionados de ciano, halo, alquilo, haloalquilo, alcoxi y haloalcoxi; R4 está seleccionado de alquilo o haloalquilo; R5 es alquilo; R6 está seleccionado de Ar1, (Ar1)alquilo, (cromanil)alquilo, cianocicloalquilo o (dihidrobenzodioxinil)alqui lo; y Ar1 es fenilo sustituido con 0-5 sustituyentes seleccionados de ciano, halo, alquilo, cicloalquilo, haloalquilo, hidroxi, alcoxi, haloalcoxi, (hidroxi)alcoxi, (alcoxi)alcoxi, fenoxi, benciloxi, carboxi, fenilo y cianocicloalquilo. (ver Fórmula).
MX2018001722A 2015-08-11 2016-08-10 Derivados del acido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridi n-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana. MX2018001722A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562203791P 2015-08-11 2015-08-11
PCT/IB2016/054832 WO2017025917A1 (en) 2015-08-11 2016-08-10 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
MX2018001722A true MX2018001722A (es) 2018-05-16

Family

ID=56851651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001722A MX2018001722A (es) 2015-08-11 2016-08-10 Derivados del acido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridi n-3-il acetico como inhibidores de la replicacion del virus de la inmunodeficiencia humana.

Country Status (23)

Country Link
US (2) US10189816B2 (es)
EP (1) EP3334716A1 (es)
JP (1) JP6782766B2 (es)
KR (1) KR20180032649A (es)
CN (1) CN108137534A (es)
AR (1) AR105653A1 (es)
AU (1) AU2016306089B2 (es)
CA (1) CA2994791A1 (es)
CL (1) CL2018000363A1 (es)
CO (1) CO2018001359A2 (es)
CR (1) CR20180091A (es)
DO (1) DOP2018000035A (es)
EA (1) EA033057B1 (es)
HK (1) HK1249503A1 (es)
IL (1) IL257240B (es)
MA (1) MA42614A (es)
MX (1) MX2018001722A (es)
PE (1) PE20181002A1 (es)
PH (1) PH12018500294A1 (es)
TW (1) TWI657086B (es)
UA (1) UA120464C2 (es)
WO (1) WO2017025917A1 (es)
ZA (1) ZA201800689B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
US10577353B2 (en) * 2015-08-12 2020-03-03 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US10407410B2 (en) 2016-05-11 2019-09-10 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2017195111A1 (en) * 2016-05-11 2017-11-16 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2019515000A (ja) * 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
EP3565810A1 (en) * 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2018127800A1 (en) * 2017-01-03 2018-07-12 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939545B2 (en) 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2574610A1 (en) 2007-11-15 2013-04-03 Gilead Sciences, Inc. Inhibitors of human immonodeficiency virus replication
US8377960B2 (en) * 2007-11-15 2013-02-19 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
ES2463720T3 (es) 2007-11-16 2014-05-29 Gilead Sciences, Inc. Inhibidores de la replicación del virus de inmunodeficiencia humana
CN101918365B (zh) 2007-11-16 2013-10-09 吉联亚科学股份有限公司 人类免疫缺陷病毒复制的抑制剂
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
US8338441B2 (en) * 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
WO2011076765A1 (en) 2009-12-23 2011-06-30 Katholieke Universiteit Leuven Novel antiviral compounds
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) * 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP2970298A1 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9527842B2 (en) 2013-03-14 2016-12-27 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
US9637501B2 (en) * 2014-02-20 2017-05-02 Viiv Healthcare Uk (No. 5) Limited Pyridin-3-yl acetic acid macrocycles as inhibitors of human immunodeficiency virus replication
US9193720B2 (en) * 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) * 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
CA2995087A1 (en) * 2015-08-12 2017-02-16 John F. Kadow 5-(n-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
US10577353B2 (en) * 2015-08-12 2020-03-03 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Also Published As

Publication number Publication date
DOP2018000035A (es) 2018-03-30
JP6782766B2 (ja) 2020-11-11
US20180230129A1 (en) 2018-08-16
CR20180091A (es) 2018-06-13
ZA201800689B (en) 2021-08-25
CO2018001359A2 (es) 2018-05-10
HK1249503A1 (zh) 2018-11-02
EA201890361A1 (ru) 2018-11-30
CN108137534A (zh) 2018-06-08
PE20181002A1 (es) 2018-06-26
EP3334716A1 (en) 2018-06-20
IL257240B (en) 2020-02-27
IL257240A (en) 2018-03-29
WO2017025917A1 (en) 2017-02-16
JP2018522927A (ja) 2018-08-16
CL2018000363A1 (es) 2018-07-06
US10189816B2 (en) 2019-01-29
CA2994791A1 (en) 2017-02-16
EA033057B1 (ru) 2019-08-30
AU2016306089A1 (en) 2018-03-01
AR105653A1 (es) 2017-10-25
PH12018500294A1 (en) 2018-08-13
TW201718549A (zh) 2017-06-01
TWI657086B (zh) 2019-04-21
MA42614A (fr) 2021-05-26
AU2016306089B2 (en) 2018-08-09
US20190092754A1 (en) 2019-03-28
KR20180032649A (ko) 2018-03-30
UA120464C2 (uk) 2019-12-10

Similar Documents

Publication Publication Date Title
PH12018500294A1 (en) 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
MX2020010737A (es) Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b.
GEP20227428B (en) Heterocyclic compounds as immunomodulators
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
SG10201805033XA (en) Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
PH12015500386B1 (en) Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX353412B (es) Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
PH12016500553A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors
MX2020011810A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
MX2016005342A (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
MX366123B (es) Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
AR099511A1 (es) Derivados del ácido piridin-3-ilacético como inhibidores de la replicación del virus de inmunodeficiencia humana
TW200833675A (en) Nicotinamide derivatives
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
TN2019000170A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
JP2017526748A5 (es)
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
AU2012360910A8 (en) Quinazolinone derivatives as HCV inhibitors